Cytochrome P450 2C8 and Cytochrome P450 2C9 (CYP2C8, CYP2C9)

Cytochrome P450 2C8 and Cytochrome P450 2C9 are highly polymorphic hepatic enzymes responsible for the oxidative metabolism of approximately 20% of all drugs in clinical use, as well as processing endogenous polyunsaturated fatty acids into bioactive epoxide derivatives. These enzymes exhibit overlapping substrate specificities and genetic polymorphisms that significantly influence individual drug responses, efficacy, and risk of adverse events. Functionally, they serve as phase I metabolizing enzymes and have important roles in cardiovascular physiology, inflammation, and cancer biology via modulation of endogenous lipid mediators. Genetic variation in CYP2C8/CYP2C9 is a major determinant of patient-specific drug dosing strategies and contributes to interindividual pharmacogenomic variability.

Other names

Cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8)Cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9)P450 2C8P450 2C9CYP2C subfamily enzymes

Drug metabolism via oxidation/epoxidation, affecting drug clearance and generating active/inactive metabolites. Alteration in enzyme activity due to genetic variants, leading to poor, intermediate, or normal drug metabolizer phenotypes.